Diabetes and obesity

Eloralintide and tirzepatide combination led to 23.3% weight loss in trial

In a 48-week phase 2 trial, the highest-dose eloralintide and tirzepatide combination was linked to 23.3% weight loss in adults with type 2 diabetes and overweight or obesity.

Reported by 2 outlets Friday, October 2, 2026

An insulin pen
Photo: CC0

Adults with type 2 diabetes and overweight or obesity who received eloralintide with tirzepatide lost up to 23.3% of their body weight over 48 weeks in a phase 2 trial, according to results presented at the European Association for the Study of Diabetes annual meeting. The trial included 367 adults. The greatest weight loss was reported with eloralintide 9 mg plus tirzepatide 15 mg. Participants receiving tirzepatide 15 mg alone lost 14.8%.

The reports differ on discontinuations due to adverse events. Healio reported that less than 10% of adults in all arms discontinued the trial for this reason. MedPage Today reported that 27% in the highest-dose combination group discontinued treatment, compared with 2.9% in the tirzepatide-alone group. Healio also reported that gastrointestinal events were most common, and that 6.5% of participants had at least one serious adverse event.

The trial used two separate injections for the combination. Healio reported that Lilly plans to co-formulate the drugs into one injection for its upcoming phase 3 trial. MedPage Today reported Lilly plans to advance the combination into phase III development by the end of the year.

Reporting on this story

More top stories

This Week in Medicine

The week in medicine, in five minutes

The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.

Free. No spam. Unsubscribe anytime.